We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App




Novel Fecal Calprotectin Test Validated in Pediatric Population

By LabMedica International staff writers
Posted on 10 Nov 2020
Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are increasingly prevalent disorders with overlapping clinical presentations. More...
Distinguishing between these two classes of disease is important, as while IBS is an idiopathic functional disorder, IBD is characterized by chronic inflammation and tissue destruction.

Fecal calprotectin (FC) is a biomarker that has shown promise for identification and monitoring of IBD. Calprotectin is a calcium- and zinc-binding protein that is abundant in polynuclear neutrophils, monocytes, and macrophages. Its concentration in stool is well correlated with disease activity of IBD, especially in respect to the colonic mucosa, as measured by histopathological examination.

Medical Scientists at Baylor College of Medicine (Houston, TX, USA) and their colleagues evaluated the Buhlmann fCal Turbo turbidimetric immunoassay (Buhlmann Diagnostics, Amherst, NH, USA) for use on the Vitros 5600 automated chemistry analyzer (Ortho Clinical Diagnostics, Raritan, NJ, USA). The fCal Turbo assay yields measurements in μg/g. Samples used for validation were extracted from stool using the Buhlmann Diagnostics’ Calex cap extraction device. Method comparison was performed with 20 fecal samples with the Buhlmann fCal ELISA, and reference range verification was performed with 33 fecal samples.

The scientists reported that the fCal Turbo assay on the Vitros 5600 was linear between 33.1 and 14,182.5 μg/g, with dilution studies extending the range to 33.1 to 22,000 μg/g, Reproducibility of the assay met acceptability criteria, with intra-assay CV of 0.3–3.2% and inter-assay CV of 5.2–8.9%. Interference studies identified acceptable thresholds for protein, bilirubin, and lipids. They verified a reference range of 33.1 to 60 μg/g in their pediatric patient population. Deming regression identified acceptable correlation with minor positive bias (2.7%) between the fCal Turbo and fCal ELISA methods. In their laboratory, the process from receipt to result was accomplished in approximately 30 minutes.

The authors concluded that the newly FDA-cleared fCal Turbo assay, with the Calex cap for sample extraction, represented a much more rapid and facile workflow for their laboratory than referring samples for analysis by ELISA. They determined that the fCal Turbo assay on the Vitros 5600 analyzer offered excellent performance relative to ELISA, was reproducible, and was not excessively prone to analytical interference. They anticipate that it will be a useful tool for identification of IBD in our patient population. The study was published on October 17, 2020 in the journal Practical Laboratory Medicine.

Related Links:
Baylor College of Medicine
Buhlmann Diagnostics
Ortho Clinical Diagnostics



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Specimen Radiography System
TrueView 200 Pro
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Increased polysialic acid in schizophrenia patients represents a potential diagnostic tool and possible target for treatment (Photo courtesy of 123RF)

New Technique for Measuring Acidic Glycan in Blood Simplifies Schizophrenia Diagnosis

Polysialic acid is a unique acidic glycan predominantly found in brain regions associated with memory and emotion, but it is also present in the bloodstream. Research has shown that blood levels of polysialic... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.